EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC-ND 4.0

Neoadjuvant Chemotherapy for Male Breast Cancer: A Retrospective Cohort Study

Zejian Yang, Peng Ni, Yu Wang, Ruixin Wang, Bo Wang, Yu Ren, Guanqun Ge, Fan Liu, Jianjun He, Can Zhou

Cancer Medicine · 2026-06 · 15 (6)

DOI: 10.1002/cam4.71987 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Cancer Medicine, online erschienen am 27.05.2026. Verfasst von Zejian Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Male, Neoadjuvant Therapy, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Clinical research project of the First Affiliated Hospital of Xi'an Jiaotong University, Innovation Capability Support Program of Shaanxi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The survival benefit of neoadjuvant chemotherapy (Neo‐CT) among male breast carcinoma (MaBC) remains unclear, and the specific population that can benefit from Neo‐CT is also not yet defined. We utilized the data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database and employed Kaplan–Meier analysis; Cox proportional hazards model and binary variable Logistic regression were performed to evaluate the effect of Neo‐CT on the therapeutic response and prognosis of MaBC patients. Among the 4171 MaBC subjects included, 194 (4.7%) patients received Neo‐CT only (Neo‐CT only group), 246 (5.9%) cases received adjuvant chemotherapy and Neo‐CT (CT + Neo‐CT group); the remaining 3731 (89.5%) cases received postoperative chemotherapy only (CT‐only group). Totally, 20 (12.12%) participants achieved pathological complete response (pCR). And patients who achieved a pCR (pCR subgroup) had improved 5‐year and 10‐year overall survival (OS) (100.0% vs. 79.70% vs. 73.81%, 100.0% vs. 59.12% vs. 28.82%, respectively) and breast cancer‐specific survival (BCSS) (86.30% vs. 91.49%, 69.04% vs. 83.32%, respectively) in comparison with those in the Non‐pCR subgroup. Further binary Logistic regression analysis showed that the achievement of pCR might be related to stage I‐II ( p = 0.007) and hormone receptor (HR) negative ( p = 0.010) disease, and the pCR rate of stage I‐II and HR− MaBC patients was 66.67%.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast Neoplasms, MaleNeoadjuvant TherapyAntineoplastic Combined Chemotherapy ProtocolsHumansMaleRetrospective StudiesPathologic Complete ResponseMiddle AgedPrognosisSEER ProgramNeoplasm StagingAgedChemotherapy, AdjuvantTreatment OutcomeKaplan-Meier EstimateAdult

Stichwörter der Autor:innen

Neoadjuvant chemotherapyTNM stagemale breast cancermolecular subtypingpCR

Autor:innen und Institutionen

  • Department of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  • School of Medicine, Xi'an Jiaotong University, Xi'an, China.
  • Department of Translational Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.

Förderung

  • Clinical research project of the First Affiliated Hospital of Xi'an Jiaotong University
  • Innovation Capability Support Program of Shaanxi

Zitieren

APA

Yang, Z., Ni, P., Wang, Y., Wang, R., Wang, B., Ren, Y., Ge, G., Liu, F., He, J., & Zhou, C. (2026). Neoadjuvant Chemotherapy for Male Breast Cancer: A Retrospective Cohort Study. Cancer Medicine, 15(6). https://doi.org/10.1002/cam4.71987

Vancouver

Yang Z, Ni P, Wang Y, Wang R, Wang B, Ren Y, et al. Neoadjuvant Chemotherapy for Male Breast Cancer: A Retrospective Cohort Study. Cancer Medicine. 2026;15(6). doi:10.1002/cam4.71987

BibTeX
@article{Yang2026,
  author = {Yang, Zejian and Ni, Peng and Wang, Yu and Wang, Ruixin and Wang, Bo and Ren, Yu and Ge, Guanqun and Liu, Fan and He, Jianjun and Zhou, Can},
  title = {Neoadjuvant Chemotherapy for Male Breast Cancer: A Retrospective Cohort Study},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {6},
  doi = {10.1002/cam4.71987}
}
Kostenlos starten →